Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP1A1 antisense RNA 1 (ATP1A1-AS1)
- Target
- ATP1A1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA)
01
Overview
ATP1A1 antisense RNA 1 (ATP1A1-AS1) is a long non-coding RNA transcribed from the antisense strand of the ATP1A1 gene. It is implicated in the regulation of vascular smooth muscle cell phenotype and apoptosis, especially in the context of intracranial aneurysms, where it is upregulated and promotes disease progression. ATP1A1-AS1 also functions as a competitive endogenous RNA, interacting with microRNAs and indirectly modulating target gene expression involved in cancer and other diseases. Its diagnostic potential is supported by upregulation in disease and its stability in exosomal form, emphasizing its value as a biomarker in clinical settings[1][2][5][6][7].
- Other names
- ATP1A1-AS1ATP1A1OSC1orf203MGC16179ATP1A1 antisense gene protein 1ATP1A1 opposite strand proteinATP1A1 opposite strand
02
Mechanism of action
Acts via antisense regulation of ATP1A1 gene expression. Serves as a competing endogenous RNA for microRNAs (e.g., miR-620). Indirectly regulates signaling pathways relevant to apoptosis, vascular cell function, and cancer.
03
Biological functions
Regulates Na/K-ATPase alpha-1 by antisense mechanismsInduces phenotype switching in vascular smooth muscle cellsPromotes apoptosis and inhibits cell proliferation in some cancer contextsModulates MMP-9 expressionFunctions as a competitive endogenous RNA interacting with microRNAs, e.g., miR-620/IRF2BP2
04
Disease associations
Intracranial aneurysm—diagnostic biomarker and pathogenic mechanismThyroid carcinoma—regulator of proliferation and apoptosisCharcot-Marie-Tooth disease, Axonal, Type 2Dd (gene-disease association)Hypomagnesemia, seizures, and impaired intellectual development 2 (gene-disease association)Potential implication in other cardiovascular and central nervous system diseases via exosomal lncRNA roles
05
Safety considerations
As a biomarker, the main clinical challenge is RNA instability in plasma, though exosomal packaging improves stabilityNotable therapeutic challenges for lncRNAs include specificity of targeting and off-target effects
06
Biomarkers
ATP1A1-AS1 is a reported biomarker for intracranial aneurysm diagnosis, detectable in exosomes and differentially expressed in disease
Beyond the preview
Go deeper on ATP1A1 antisense RNA 1 (ATP1A1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATP1A1 antisense RNA 1 (ATP1A1-AS1).